Latest revenue
$29.6M
as of 2026-03-31
Latest net income
$-5.1M
as of 2026-03-31
Net margin
-17.1%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ANIK is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for ANIK.
5-year trend
What this company does
Purpose and Mission Founded in 1992, Anika Therapeutics, Inc. (“Anika” or “Company”) is a global leader in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The Company leverages proprietary hyaluronic acid (“HA”) technology to develop highly differentiated products. Driven by strong partnerships with physicians, Anika is dedicated to pioneering HA-based innovations that redefine orthopedic care. Our mission is to restore active living, empower surgeon choice, and enhance patient outcomes worldwide. Anika’s Mission: “Together, we restore active living and redefine what’s possible with hyaluronic acid.” Anika’s Core Values: ● Trust and…
AI summary unavailable — showing raw filing excerpt
Generated from ANIK's filing dated 2026-03-03
Key risks
Our operating results and financial condition have varied in the past and could vary significantly in the future depending on a number of factors. You should consider carefully the risks and uncertainties described below, in addition to the other information contained in this Annual Report on Form 10-K, before deciding whether to purchase our common stock. If any of the following risks actually occur, our business, financial condition, results of operations, and future prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and stockholders could lose part or all of their investment. Risks Related to Our Business and Industry…
AI summary unavailable — showing raw filing excerpt
Generated from ANIK's filing dated 2026-03-03
Profitability
Gross margin
56.6%
10.8%Operating margin
-9.8%
130.3%Net margin
-9.6%
79.5%Return on equity
-7.1%
73.4%Return on assets
-5.7%
79.4%Leverage
Debt / equity
0.24×
625.1%Debt / assets
19.1%
505.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $29.6M | +13.2% | $-5.1M | -3.8% | -17.1% |
Q4 2025 2025-12-31 | $30.6M | +0.0% | $292.0K | +101.3% | 1.0% |
Q3 2025 2025-09-30 | $27.8M | -5.9% | $-2.3M | +92.2% | -8.4% |
Q2 2025 2025-06-30 | $28.2M | -8.2% | $-4.0M | -4411.4% | -14.1% |
Q1 2025 2025-03-31 | $26.2M | -9.8% | $-4.9M | -8.0% | -18.6% |
Q4 2024 2024-12-31 | $30.6M | — | $-21.9M | — | -71.4% |
Q3 2024 2024-09-30 | $29.6M | -28.7% | $-29.9M | -355.0% | -101.2% |
Q2 2024 2024-06-30 | $30.7M | -30.6% | $-88.0K | +96.8% | -0.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on ANIK — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$223.2K
Insider selling
$0
Net activity
+$223.2K
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2026-05-01 | John B Henneman III Director | Purchase | 5,000 | $14.66 | $73.3K | |
| 2026-04-30 | Stephen D. Griffin President and CEO | Purchase | 12,200 | $12.29 | $149.9K |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANIK
Institutional value
$70.0M
Total shares held
5.5M
Distinct holders
66
-59 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1.6M | $23.1M | -59.6K (-3.6%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 605.8K | $8.8M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 458.8K | $6.7M | -35.5K (-7.2%) | Trimmed |
| 4 | CAPITAL MANAGEMENT CORP /VA | 447.7K | $6.5M | -52.7K (-10.5%) | Trimmed |
| 5 | DEUTSCHE BANK AG\ | 353.2K | $5.1M | +271.9K (+334.5%) | Added |
| 6 | UBS Group AG | 133.1K | $1.9M | +104.5K (+366.2%) | Added |
| 7 | Nuveen, LLC | 120.7K | $1.8M | +67.5K (+126.9%) | Added |
| 8 | ENVESTNET ASSET MANAGEMENT INC | 110.1K | $1.6M | -7.8K (-6.6%) | Trimmed |
| 9 | Jefferies Financial Group Inc. | 93.5K | $1.4M | — | New |
| 10 | VANGUARD FIDUCIARY TRUST CO | 90.4K | $1.3M | — | New |
| 11 | GLOBEFLEX CAPITAL L P | 87.6K | $1.3M | +0 (+0.0%) | No change |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 72.2K | $1.0M | — | New |
| 13 | JANE STREET GROUP, LLC | 54.4K | $789.1K | -80.3K (-59.6%) | Trimmed |
| 14 | HSBC HOLDINGS PLC | 50.3K | $729.2K | -46.4K (-48.0%) | Trimmed |
| 15 | R Squared Ltd | 50.2K | $727.7K | +8.6K (+20.7%) | Added |
| 16 | Advyzon Investment Management, LLC | 49.9K | $722.9K | +1.6K (+3.2%) | Added |
| 17 | Indivisible Partners | 49.8K | $721.5K | -645 (-1.3%) | Trimmed |
| 18 | BNP PARIBAS FINANCIAL MARKETS | 47.2K | $684.7K | -25.0K (-34.6%) | Trimmed |
| 19 | Assenagon Asset Management S.A. | 46.6K | $675.5K | +34.0K (+268.7%) | Added |
| 20 | Bank of New York Mellon Corp | 39.8K | $576.6K | -738 (-1.8%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANIK's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.